Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + nab-paclitaxel in advanced gastric cancer
NCT04572542Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric adenocarcinoma, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04572542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572542.